Orexo enters into reimbursement agreement with UHG and OptumRx for Zubsolv

Under the agreement, Zubsolv will be given preferred, Tier 2 brand status on UHG commercial employer and individual formularies managed by OptumRx for the maintenance treatment of opioid dependence through 30 June 2014.

Beginning on 1 July 2014 Zubsolv will become the only buprenorphine/naloxone combination product on all of UHG’s closed and highly managed health plan formularies, inclusive of all brand and generic formulations.

Orexo CEO and president Nikolaj Sorensen noted the company is dedicated to broadening the market access position for Zubsolv and this agreement with UHG and OptumRx is an important step in that direction.

"It is a major achievement and endorsement as health insurers with a firm control over their formularies recognize ZUBSOLV as the preferred buprenorphine/naloxone formulary product for the maintenance treatment of opioid dependence," Sorensen added.

Zubsolv is an advanced sublingual tablet formulation for maintenance treatment of opioid dependence with high bioavailability, a fast dissolve time, small tablet size, and menthol flavor. The advanced formulation provided by Zubsolv was specifically designed to meet the needs expressed by patients.

Meeting patient needs may have the potential to improve patient adherence, thus reducing relapse rates and improving successful patient outcomes. It is the only opioid dependence treatment option available in the highest level of child resistant, unit dose, F1 packaging, designed to reduce the chance of unintended pediatric exposure.